genetic research — The Cyprus Institute of Neurology and Genetics (CING) is making significant strides in genetic research with its recent acquisition of an advanced spatial transcriptomics platform for biological tissue analysis. This cutting-edge technology is poised to enhance precision medicine in Cyprus, marking a pivotal advancement for the research community.
Genetic research: A Landmark Investment in Cancer Research
The acquisition, backed by a €500,000 grant from the Research and Innovation Foundation (RIF), will support the Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology at CING. This investment is part of a broader initiative under Cyprus’ Recovery and Resilience Plan titled “Cyprus Tomorrow,” which is funded by the European Union’s Next Generation EU.
Transforming the Study of Gene Expression
The spatial transcriptomics platform enables scientists to study gene expression in the context of biological tissue. This innovative tool allows for the simultaneous detection of thousands of genes in individual tissue sections, as well as the co-detection of proteins. Such capabilities pave the way for advanced multimodal studies that can lead to breakthroughs in understanding cancer.
Advancing Precision Medicine for Better Patient Outcomes
CING emphasises that this new technology positions Cyprus at the forefront of international scientific progress. According to the institute, the system represents not just a technological upgrade but also a strategic investment in knowledge and innovation. Dr Fotios Bekris, project coordinator and Director of the Department, expressed gratitude to RIF for its support, highlighting the collaboration among his colleagues as essential to the success of the proposal.
Collaboration Fuels Progress
The project is the result of close scientific cooperation involving Dr Bekris and his team, including Dr Andreas Chatzisavvas, Dr Sotiris Kyriakou, Dr Aikaterini Cheimona, Dr George M. Spyrou, and Dr Kyriaki Michaelidou. Together, they have laid the groundwork for research that promises to transform cancer genetics in Cyprus.
Immediate Benefits for Patients
CING believes that the new platform will yield immediate benefits for patients by facilitating more targeted and personalised treatment options. It opens new avenues for discoveries in cancer prevention, diagnosis, and therapy, potentially revolutionising how healthcare is approached in the region.
